These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7959421)

  • 21. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
    Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
    Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Z-103 on TNB-induced colitis in rats.
    Yoshikawa T; Yamaguchi T; Yoshida N; Yamamoto H; Kitazumi S; Takahashi S; Naito Y; Kondo M
    Digestion; 1997; 58(5):464-8. PubMed ID: 9383638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution of mesalazine enemas in active and quiescent ulcerative colitis.
    van Bodegraven AA; Boer RO; Lourens J; Tuynman HA; Sindram JW
    Aliment Pharmacol Ther; 1996 Jun; 10(3):327-32. PubMed ID: 8791959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutic development: mesalazine.
    Osterwald HP
    Scand J Gastroenterol Suppl; 1990; 172():43-6. PubMed ID: 2353170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy.
    Karrout Y; Dubuquoy L; Piveteau C; Siepmann F; Moussa E; Wils D; Beghyn T; Neut C; Flament MP; Guerin-Deremaux L; Dubreuil L; Deprez B; Desreumaux P; Siepmann J
    J Control Release; 2015 Jan; 197():121-30. PubMed ID: 25445696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: aminosalicylates in inflammatory bowel disease.
    Hanauer SB
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis.
    Kjaergaard N; Christensen LA; Lauritsen JG; Rasmussen SN; Hansen SH
    Scand J Gastroenterol; 1989 Sep; 24(7):891-6. PubMed ID: 2572047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delivery and fate of oral mesalamine microgranules within the human small intestine.
    Layer PH; Goebell H; Keller J; Dignass A; Klotz U
    Gastroenterology; 1995 May; 108(5):1427-33. PubMed ID: 7729635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs.
    Goto M; Okamoto Y; Yamamoto M; Aki H
    J Pharm Pharmacol; 2001 Dec; 53(12):1711-20. PubMed ID: 11804402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet.
    Wilding IR; Kenyon CJ; Hooper G
    Aliment Pharmacol Ther; 2000 Feb; 14(2):163-9. PubMed ID: 10651656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines.
    Zwolinska-Wcislo M; Krzysiek-Maczka G; Ptak-Belowska A; Karczewska E; Pajdo R; Sliwowski Z; Urbanczyk K; Drozdowicz D; Konturek SJ; Pawlik WW; Brzozowski T
    J Physiol Pharmacol; 2011 Jun; 62(3):357-68. PubMed ID: 21893697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intestinal anti-inflammatory activity of the seeds of Raphanus sativus L. in experimental ulcerative colitis models.
    Choi KC; Cho SW; Kook SH; Chun SR; Bhattarai G; Poudel SB; Kim MK; Lee KY; Lee JC
    J Ethnopharmacol; 2016 Feb; 179():55-65. PubMed ID: 26721217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of mesalazine, metronidazole and gentamicin on bacterial translocation in experimental colitis.
    Yigitler C; Gulec B; Aydogan H; Ozcan A; Kilinc M; Yigit T; Kozak O; Pekcan M
    J Gastroenterol Hepatol; 2004 Oct; 19(10):1179-86. PubMed ID: 15377297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1992 Oct; 27(10):863-8. PubMed ID: 1359629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
    Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
    J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
    Sann H; Erichsen Jv; Hessmann M; Pahl A; Hoffmeyer A
    Life Sci; 2013 Apr; 92(12):708-18. PubMed ID: 23399699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions.
    Jacobsen BA; Abildgaard K; Rasmussen HH; Christensen LA; Fallingborg J; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1991 Apr; 26(4):374-8. PubMed ID: 2034991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.